Onconetix, Inc. (ONCO)
NASDAQ: ONCO · Real-Time Price · USD
1.200
-0.090 (-6.98%)
Apr 8, 2026, 12:56 PM EDT - Market open
Company Description
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology in the United States, the European Union, and Non-European Union.
The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test.
The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.
Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
Onconetix, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 18, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | David White |
Contact Details
Address: 201 East Fifth Street, Suite 1900 Cincinnati, Ohio 45202 United States | |
| Phone | 513 620 4101 |
| Website | onconetix.com |
Stock Details
| Ticker Symbol | ONCO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $9.00 |
| CIK Code | 1782107 |
| CUSIP Number | 68237Q302 |
| ISIN Number | US68237Q3020 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Karina M. Fedasz | Interim Chief Executive Officer and Interim Chief Financial Officer |
| Andrew D. Skibo Ph.D. | Global Head of Biologics Operations |
| Dr. Brian Price Ph.D. | Head of Technology Strategy |
| Theodore Scott Yoho | Head of Business Development |
| Dr. Ali I. Fattom Ph.D. | Head of Science and Discovery |
| Dr. Jay Newmark M.B.A., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2026 | 425 | Filing |
| Mar 31, 2026 | 425 | Filing |
| Mar 30, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2026 | 8-K | Current Report |
| Mar 25, 2026 | 425 | Filing |
| Mar 25, 2026 | 8-K/A | [Amend] Current report |
| Mar 24, 2026 | 8-K | Current Report |
| Mar 18, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 13, 2026 | 10-K | Annual Report |
| Feb 12, 2026 | 425 | Filing |